Global Acute Migraine Treatment Market Outlook 2024, Forecast To 2033
24 Sep, 2024
The acute migraine treatment market is experiencing rapid growth, rising from $2.35 billion in 2023 to $2.60 billion in 2024, reflecting a CAGR of 11.0%. This growth is driven by increasing prevalence of migraines and investment in migraine research. The market is projected to reach $4.00 billion by 2028, growing at a CAGR of 11.3%. Future expansion is supported by the demand for non-invasive treatment options and personalized drug development. Key trends include advancements in neuromodulation devices and the rise of telemedicine for improved patient outcomes.
Major Driver In The Acute Migraine Treatment Market
The acute migraine treatment market is set to expand, driven by rising work pressures. Job-related stressors—including tight deadlines and poor work-life balance—can exacerbate migraine conditions, necessitating effective treatment options. According to Mental Health America, 81% of workers reported that workplace stress affected their mental health in 2023, an increase from 78% in 2021. This growing concern underscores the demand for innovative migraine treatments.
Request A Free Sample Of The Acute Migraine Treatment Market ReportAcute Migraine Treatment Market Competitive Landscape
Pfizer Inc., Johnson And Johnson, Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Viatris Inc., Allergan plc, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Endo International plc, Supernus Pharmaceuticals Inc., Collegium Pharmaceutical Inc., Upsher-Smith Laboratories LLC, BioDelivery Sciences International Inc., Axsome Therapeutics Inc., Impel NeuroPharma Inc., Currax Pharmaceuticals LLC, Satsuma Pharmaceuticals Inc.
Key Acute Migraine Treatment Market Trend
In the acute migraine treatment market, companies are innovating with products like migraine nasal sprays to improve efficacy and convenience for sufferers. These sprays deliver medication via the nasal passages for faster relief. Pfizer Inc. launched ZAVZPRET (zavegepant) Migraine Nasal Spray in March 2023, which has received FDA approval. This rapid-acting formulation provides relief within 15 minutes by blocking the CGRP pathway, making it a valuable option for those experiencing severe migraine symptoms.
Purchase The Global Acute Migraine Treatment Market Report Directly And Get A Swift Delivery
Acute Migraine Treatment Market Segmentation
The acute migraine treatment market covered in this report is segmented –
1) By Drug Type: Triptans, Calcitonin Gene-Related Peptide Antagonist, Nonsteroidal Anti-Inflammatory Drugs, Beta-Adrenergic, Ergot Alkaloids, Other Drug Types
2) By Route Of Administration: Oral, Injection, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, E-Commerce
By Geography:The regions covered in the acute migraine treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the acute migraine treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period.
The Acute Migraine Treatment Global Market Report 2024 furnishes information about the global acute migraine treatment market, encompassing details like market size, projections for growth, segmentation across various sectors and regions, and an overview of competitors, including their revenues, profiles, and market shares. Furthermore, the report pinpoints potential opportunities and strategic directions derived from market trends and the strategies adopted by key competitors. The report also offers an assessment of how the COVID-19 pandemic, the Russia-Ukraine conflict, and increasing inflation have affected both global and regional markets, furnishing valuable strategic insights for businesses.